The cannabinoid system interacts with toll-like receptor signaling in multiple sclerosis, revealing how Sativex might work | Research

The takeaway

A review found novel interplay between toll-like receptor (TLR) immune signaling and the cannabinoid system, both centrally and peripherally, helping explain how cannabis-based MS treatments like Sativex may reduce inflammation and symptoms.

Read this if you want to understand the molecular mechanisms behind how cannabis-based medicines may work in MS.

Cannabinoids modulate TLR immune signaling both centrally and peripherally in MS

What the researchers found

Toll-like receptors (TLRs) are immune sensors that trigger inflammatory responses and play a pivotal role in the development of MS (as shown in animal models). The review presented evidence that cannabinoids modulate TLR signaling pathways both in the brain and in peripheral immune cells.

Sativex, a combination of plant cannabinoids approved for MS, has demonstrated efficacy for neuropathic pain and spasticity, but its precise cellular and molecular mechanisms have remained unclear. The review highlighted that cannabinoid-TLR interactions may partly explain how Sativex works, by dampening the innate immune responses that drive MS pathology.

Why it matters

Understanding how cannabis-based medicines work at the molecular level is essential for developing better treatments. The TLR connection suggests that cannabinoids may be addressing a fundamental driver of MS inflammation, not just masking symptoms, and could lead to more targeted therapies.

The numbers in context

Sativex: plant-derived cannabinoid combination with clinical efficacy for MS pain and spasticity. TLR signaling: pivotal in EAE (animal MS model) development. Cannabinoid-TLR interplay: demonstrated both centrally and peripherally.

How the study worked

Narrative review synthesizing evidence on TLR signaling in MS pathogenesis and its modulation by cannabinoids, both in the central nervous system and peripheral immune system.

What this study cannot tell us

Narrative review based largely on preclinical and in vitro data. The specific mechanisms by which Sativex modulates TLR signaling in MS patients have not been confirmed in clinical studies. TLR biology is complex, and cannabinoid effects may vary by TLR type and cell context.

How to read the evidence

Narrative review linking two biological systems. Provides mechanistic framework but direct evidence in MS patients is limited.

When this study was published

Published in 2017. The TLR-cannabinoid interaction in neuroinflammation continues to be investigated.

The bigger picture

TLR signaling is one of the most fundamental immune mechanisms, and its dysregulation drives many autoimmune diseases beyond MS. If cannabinoids can modulate TLR signaling broadly, this could have implications for conditions like rheumatoid arthritis, lupus, and inflammatory bowel disease.

Questions still open

Which specific TLR pathways are most affected by cannabinoids? Would targeting TLR signaling directly be more effective than using whole-plant cannabinoids? Could TLR-cannabinoid interactions be used as biomarkers to predict which MS patients will respond to Sativex?

Common questions

What are toll-like receptors?

TLRs are immune sensors on cell surfaces that detect pathogen-associated molecules and trigger inflammatory responses. In MS, TLR signaling is overactive, contributing to the autoimmune attack on nerve insulation (myelin). Cannabinoids appear to dial down this TLR-driven inflammation.

How does Sativex work for MS?

Sativex contains THC and CBD. This review suggests it may work partly by modulating TLR signaling, reducing the innate immune responses that drive MS inflammation. This would explain its effects on both pain and spasticity, as both are influenced by neuroinflammation.

Read the original research

Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.

Neuropharmacology, 113(Pt B), 618-626

View on PubMed ↗Publisher’s paper ↗

Citation

Fitzpatrick, John-Mark K; Downer, Eric J. (2017). Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.. Neuropharmacology, 113(Pt B), 618-626. https://doi.org/10.1016/j.neuropharm.2016.04.009